DUBLIN, Calif., Dec 03, 2010 (BUSINESS WIRE) --
SuperGen, Inc. (NASDAQ:SUPG) today announced that a summary of preclinical efficacy, safety, and pharmacokinetics data of SGI-110 will be presented at the American Society of Hematology in Orlando on Saturday, December 4, 2010 at 5:30 pm ET. The title of the poster presentation will be "SGI-110, a novel second generation potent DNA methylation inhibitor, in development for the treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA methylation results of a low volume subcutaneous (SC) formulation."
SGI-110 has received clearance from the Food and Drug Administration to advance into Phase I trials. The clinical trial has been initiated at MD Anderson Cancer Center and other centers are being initiated.
"SGI-110 is a low volume, easy to administer, subcutaneous drug with a pre-clinical profile that has demonstrated potent hypomethylation and epigenetic modulation with less frequent administration than currently marketed hypomethylating agents," said Mohammad Azab, M.D., Chief Medical Officer. "Its preclinical anticancer and hypomethylating effects have been observed in both hematological and solid tumors models."
SGI-110 is a small molecule, DNA hypomethylating agent. It is intended to follow up on the Company's currently marketed product, Dacogen® (decitabine) for Injection that is licensed and marketed by Eisai and Johnson and Johnson. In preclinical studies, SGI-110 has shown potential to be administered with dosing schedules less frequent than currently marketed products. SuperGen is working with the Epigenetics Dream Team of the Stand Up to Cancer Foundation to develop this drug.
SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the overall success of the Phase I trial protocol for SGI-110, our ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
SOURCE: SuperGen, Inc.
Timothy L. Enns, (925) 560-2810
Senior Vice President
Corporate Communications & Business Development
Susanna Chau, (925) 560-2845